beta Amyloid antibody

Catalog No. ABIN1580412

This anti-beta Amyloid antibody is a Mouse Monoclonal antibody detecting beta Amyloid in WB, IHC, IF and ICC. Suitable for Human.

Quick Overview for beta Amyloid antibody (ABIN1580412)

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This beta Amyloid antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: AB9

Product Details anti-beta Amyloid Antibody

Purification: affinity purified antibody

Isotype: IgG2a

Application Details

Application Notes: The antibody solution can be used at dilutions of 1:1,000 or higher in immunofluorescence experiments. In western blotting using chemiluminescence it can be used at dilutions of 1:1,000-2,000.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4°C short term or -20°C long term.

Target Details for beta Amyloid

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Background: Alzheimer's disease (AD) is a serious and common age related dementia which is characterized by the formation of senile plaques and neurofibrillary tangles. Senile plaques are extracellular accumulations of insoluble proteins found in cortical regions. A major component of senile plaques is beta,-amyloid, a.k.a. Abeta, a peptide predominantly of 42 or 40 amino acids. The Abeta, peptide is derived from a section of the membrane spanning domain and the immediate extracellular region of a much larger protein called the amyloid precursor protein (APP). This is an abundant protein of poorly understood function. The Abeta, peptides are generated by the activity of proteases called secretases, specifically the beta, and gamma, secretases. Certain mutations in the APP gene are associated with familial forms of AD, as are mutations in the genes encoding proteins forming the secretase enzymes, in line with the hypothesis that Abeta, accumulation is central to the AD disease process. Our antibody recognizes amino acids 1-16 of the Abeta, peptide and works well on western blots, on formalin fixed sections and as a capture reagent in ELISA. It was originally developed in the Mayo Clinic in Jacksonville in the laboratory of Dr. Todd Golde.

Pathways: Inflammasome